




Amendments to the Claims

1. (currently amended) A compound of formula (I) or a salt thereof ~~(in particular, a pharmaceutically acceptable salt thereof)~~:



wherein:

W is Ar, $-CR^4R^5Ar$ or a group (y) or (y1) wherein:




wherein m is 1 or 2;

R¹ is C₁₋₄alkyl, C₁₋₃fluoroalkyl, or $-CH_2CH_2OH$;

R² is C₂₋₆alkyl, C₃₋₆cycloalkyl or $-(CH_2)_{n^4}C_{3-6}$ cycloalkyl, wherein n⁴ is 1 or 2;

R³ is optionally substituted C₃₋₈cycloalkyl or optionally substituted mono-unsaturated-C₅₋₇cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc);



in which n¹ and n² independently are 1 or 2; and in which Y is O, S, SO₂, or NR¹⁰; where R¹⁰ is a hydrogen atom (H) hydrogen, C₁₋₂alkyl, C₁₋₂fluoroalkyl, CH₂C(O)NH₂, C(O)NH₂, C(O)NHMe, C(O)-C₁₋₂alkyl, C(O)-C₁fluoroalkyl or $-C(O)-CH_2O-C_{1-2}$ alkyl;

and wherein in R³ the C₃-cycloalkyl or the heterocyclic group of sub-formula (aa), (bb) or (cc) is optionally substituted on a ring carbon with one or two substituents independently being which are oxo (=O); OH; C₁-alkoxy; C₁-fluoroalkoxy; NHR²¹ wherein R²¹ is ~~a hydrogen atom (H)~~ hydrogen or C₁-4 straight-chain alkyl; C₁-alkyl; C₁-fluoroalkyl; -CH₂OH; -CH₂CH₂OH; -CH₂NHR²² wherein R²² is H or C₁-alkyl; -C(O)OR²³ wherein R²³ is H or C₁-alkyl; -C(O)NHR²⁴ wherein R²⁴ is H or C₁-alkyl; -C(O)R²⁵ wherein R²⁵ is C₁-alkyl; fluoro; hydroxyimino (=N-OH); or ~~(C₁-alkoxy)imino (=N-OR²⁶ where R²⁶ is C₁-alkyl)~~ hydroxyimino (=N-OH); or (C₁-alkoxy)imino (=N-OR²⁶ where R²⁶ is C₁-alkyl); and wherein any OH, alkoxy, fluoroalkoxy or NHR²¹ substituent is not substituted at the R³ ring carbon attached (~~bonded~~) to the -NH- group of formula (I) and is not substituted at either R³ ring carbon bonded to the Y group of the heterocyclic group (aa), (bb) or (cc);

and wherein, when R³ is optionally substituted mono-unsaturated-C₅-7cycloalkenyl, then the cycloalkenyl is optionally substituted with one substituent being which is fluoro or C₁-alkyl or two substituents independently being which are fluoro or methyl, and the R³ ring carbon bonded to the -NH- group of formula (I) does not partake in the cycloalkenyl double bond;



or R³ is a bicyclic group of sub-formula (ee): (ee) wherein Y¹, Y² and Y³ independently are CH₂ or oxygen (O) provided that no more than one of Y¹, Y² and Y³ is oxygen (O);

and wherein:

R⁴ and R⁵ are independently ~~a hydrogen atom (H)~~ hydrogen, methyl, ethyl, n-propyl, isopropyl, C₁-fluoroalkyl, cyclopropyl, -CH₂OR^{4a}, -CH(Me)OR^{4a}, or -CH₂CH₂OR^{4a}, wherein R^{4a} is ~~a hydrogen atom (H)~~ hydrogen, methyl (Me), or C₁fluoroalkyl such as CF₃ or CHF₂.

and wherein, in sub-formula (x) (y) and (y1):

A is C-R^{6A}, nitrogen(~~N~~) or nitrogen-oxide(~~N⁺-O⁻~~),

B is C-R^{6B}, nitrogen(~~N~~) or nitrogen-oxide(~~N⁺-O⁻~~),

D is C-R^{6D}, nitrogen(~~N~~) or nitrogen-oxide(~~N⁺-O⁻~~),

E is C-R^{6E}, nitrogen(~~N~~) or nitrogen-oxide(~~N⁺-O⁻~~),

F is C-R^{6F}, nitrogen(~~N~~) or nitrogen-oxide(~~N⁺-O⁻~~),

wherein, R^{6A}, R^{6B}, R^{6D}, R^{6E} and R^{6F} independently are: ~~a hydrogen atom (H)~~ hydrogen,

a halogen atom; C₁-alkyl; C₁-fluoroalkyl; C₃-cycloalkyl; C₁-alkoxy; C₁-fluoroalkoxy; C₃-cycloalkyloxy; -C(O)R^{16a}; -C(O)OR³⁰; -S(O)₂-R^{16a};

R^{16a} -S(O)₂-NR^{15a}; R⁷R⁸N-S(O)₂; C₁₋₂alkyl-C(O)-R^{15a}N-S(O)₂; C₁₋₄alkyl-S(O)-, Ph-S(O)-, R⁷R⁸N-CO-; -NR¹⁵-C(O)R^{16a}; R⁷R⁸N; nitro (-NO₂); OH (including any tautomer thereof); C₁₋₄alkoxymethyl; C₁₋₄alkoxyethyl; C₁₋₂alkyl-S(O)₂-CH₂; R⁷R⁸N-S(O)₂-CH₂; C₁₋₂alkyl-S(O)₂-NR^{15a}-CH₂; -CH₂-OH; -CH₂CH₂-OH; -CH₂-NR^{7R8}; -CH₂-CH₂-NR^{7R8}; -CH₂-C(O)OR³⁰; -CH₂-C(O)-NR^{7R8}; -CH₂-NR^{15a}-C(O)-C₁₋₃alkyl; -(CH₂)_n¹⁴-Het¹ where n¹⁴ is 0 or 1; cyano (-CN); Ar^{5b}; or phenyl, pyridinyl or pyrimidinyl wherein the phenyl, pyridinyl or pyrimidinyl independently are optionally substituted by one or two ~~of~~-groups which are fluoro, chloro, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy or C₁fluoroalkoxy;

and/or two adjacent groups selected from the group consisting of R^{6A}, R^{6B}, R^{6D}, R^{6E} and R^{6F} are taken together and are: -CH=CH-CH=CH₂-, -(CH₂)_n^{14a}- where n^{14a} is 3, 4 or 5, -O-(CMe₂)-O-, -O-(CH₂)_n^{14b}-O- where n^{14b} is 1 or 2; -CH=CH-NR^{15b};- -N=CH-NR^{15b};- -CH=N-NR^{15b};- -N=N-NR^{15b};- -CH=CH-O-; -N=CH-O-; -CH=CH-S-; or -N=CH-S-; wherein R^{15b} is H or C₁₋₂alkyl;

provided that:

two or more of A, B, D, E and F are independently C-H (carbon-hydrogen), C-F (carbon-fluorine), nitrogen (~~N~~), or nitrogen-oxide (~~N⁺-O⁻~~);

and no more than two of A, B, D, E and F are independently nitrogen or nitrogen-oxide (~~N⁺-O⁻~~), and no more than one of A, B, D, E and F is nitrogen-oxide (~~N⁺-O⁻~~);

and wherein, in sub-formula (z):

G is O or S or NR⁹ wherein R⁹ is a hydrogen atom (~~H~~) hydrogen, C₁₋₄alkyl, or C₁₋₂fluoroalkyl;

J is C-R^{6J}, C-[connection point to formula (I)], or nitrogen (~~N~~),

L is C-R^{6L}, C-[connection point to formula (I)], or nitrogen (~~N~~),

M is C-R^{6M}, C-[connection point to formula (I)], or nitrogen (~~N~~),

Q is C-R^{6Q}, C-[connection point to formula (I)], or nitrogen (~~N~~),

wherein, R^{6J}, R^{6L}, R^{6M} and R^{6Q} independently are: a hydrogen atom (~~H~~) hydrogen, a halogen atom; C₁₋₄alkyl; C₁₋₃fluoroalkyl; C₃₋₆cycloalkyl; C₁₋₄alkoxy; C₁₋₂fluoroalkoxy; C₃₋₆cycloalkyloxy; OH (including any tautomer thereof); or phenyl optionally substituted by one or two substituents independently being fluoro, chloro, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy or C₁fluoroalkoxy;

provided that:

two or more of J, L, M and Q are independently C-H, C-F, C-C₁₋₂alkyl,

C-[connection point to formula (I)], or nitrogen (~~N~~);

and no more than three of J, L, M and Q are nitrogen (~~N~~);

and wherein:

R⁷ and R⁸ are independently a hydrogen atom (~~H~~) hydrogen; C₁₋₄alkyl;

C₃₋₆cycloalkyl; or phenyl optionally substituted by one or two substituents independently being: fluoro, chloro, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy or C₁fluoroalkoxy;

or R⁷ and R⁸ together are -(CH₂)_n⁶- or -C(O)-(CH₂)_n⁷- or -C(O)-(CH₂)_n¹⁰-C(O)- or -(CH₂)_n⁸-X⁷-(CH₂)_n⁹- or -C(O)-X⁷-(CH₂)_n¹⁰- in which: n⁶ is 3, 4, 5 or 6, n⁷ is 2, 3, 4, or 5, n⁸ and n⁹ and n¹⁰ independently are 2 or 3, and X⁷ is O or NR¹⁴;

R^{7a} is a hydrogen atom (~~H~~) hydrogen or C₁₋₄alkyl;

R^{8a} is a hydrogen atom (~~H~~) hydrogen or methyl;

R¹⁴, R¹⁷ and R^{17a} independently are: ~~a hydrogen atom (H) hydrogen~~; C₁₋₄alkyl; C₁₋₂fluoroalkyl (e.g. CF₃); cyclopropyl; -C(O)-C₁₋₄alkyl; -C(O)NR^{7a}R^{8a}; or -S(O)₂-C₁₋₄alkyl;

R^{15a}, independent of other R^{15a}, is ~~a hydrogen atom (H) hydrogen~~ or C₁₋₄alkyl; R^{16a} is:

C₁₋₆alkyl;

C₃₋₆cycloalkyl optionally substituted by one oxo (=O), OH or C₁₋₂alkyl substituent;

C₃₋₆cycloalkyl-CH₂-;

pyridinyl optionally substituted on a ring carbon atom by one of: a halogen atom,

C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy or C₁fluoroalkoxy;

Ar^{5c};

phenyl optionally substituted by one or two substituents independently being: a halogen atom, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy or C₁fluoroalkoxy; benzyl optionally substituted on its ring by one or two substituents independently being: a halogen atom, C₁₋₂alkyl, C₁fluoroalkyl, C₁₋₂alkoxy or C₁fluoroalkoxy; or a 4-, 5-, 6- or 7-membered saturated heterocyclic ring connected at a ring-carbon and containing one or two ring-hetero-atoms independently selected from O, S, and N; wherein any ring-nitrogens which are present are present as NR²⁷ where R²⁷ is H, C₁₋₂alkyl or -C(O)Me; and wherein the ring is optionally substituted at carbon by one C₁₋₂alkyl or oxo (=O) substituent, provided that any oxo (=O) substituent is substituted at a ring-carbon atom bonded to a ring-nitrogen;

R³⁰, independent of other R³⁰, is ~~a hydrogen atom (H) hydrogen~~, C₁₋₄alkyl or C₃₋₆cycloalkyl;

Ar^{5b} and Ar^{5c} independently ~~is~~ are a 5-membered aromatic heterocyclic ring containing one O, S or NR^{15a} in the 5-membered ring, wherein the 5-membered ring can optionally additionally contain one or two N atoms, and wherein the heterocyclic ring is optionally substituted on a ring carbon atom by one of: ~~a halogen atom-halo~~, C₁₋₂alkyl, C₁fluoroalkyl, -CH₂OH, -CH₂-OC₁₋₂alkyl, OH (~~including the keto-tautomer thereof~~) or -CH₂-NR²⁸R²⁹ wherein R²⁸ and R²⁹ independently are H or methyl; and

Het¹ is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring connected at a ring-carbon and containing one or two ring-hetero-atoms independently selected from the group consisting of O, S, and N; wherein any ring-nitrogens which are present are present as NR³¹ where R³¹ is H, C₁₋₂alkyl or -C(O)Me; and wherein the ring is optionally substituted at carbon by one C₁₋₂alkyl or oxo (=O) substituent, provided that any oxo (=O) substituent is substituted at a ring-carbon atom bonded to a ring-nitrogen.


2. (original) A compound or salt as claimed in claim 1, wherein R¹ is C₂₋₃alkyl, C₂fluoroalkyl or -CH₂CH₂OH.

3. (original) A compound or salt as claimed in claim 2, wherein R¹ is ethyl, n-propyl or -CH₂CH₂OH.


4. (original) A compound or salt as claimed in claim 3, wherein R¹ is ethyl.

5. (currently amended) A compound or salt as claimed in claim 1, 2, 3 or 4, wherein R² is C₂₋₄alkyl, C₃₋₅cycloalkyl or -CH₂cyclopropyl.
6. (original) A compound or salt as claimed in claim 5, wherein R² is ethyl, propyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclopropylmethyl.
7. (currently amended) A compound or salt as claimed ~~in claim 1 any preceding claim,~~ wherein in R³ there is one substituent or no substituent.
8. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim,~~ wherein R³ is the optionally substituted C₃₋₈cycloalkyl or the optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc).
9. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim,~~ wherein, when R³ is optionally substituted C₃₋₈cycloalkyl, it is optionally substituted cyclohexyl.
10. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim,~~ wherein, when R³ is optionally substituted C₃₋₈cycloalkyl, then R³ is C₆₋₇cycloalkyl optionally substituted with one or two substituents independently ~~being selected from the group consisting of~~ oxo (=O); OH; NHR²¹ wherein R²¹ is ~~a hydrogen atom (H) hydrogen;~~ methyl; -CH₂F; -CHF₂; -C(O)OR²³ wherein R²³ is H; -C(O)NHR²⁴ wherein R²⁴ is H; fluoro; hydroxyimino (=N-OH); ~~or and~~ methoxyimino (=N-OR²⁶ where R²⁶ is methyl).
11. (currently amended) A compound or salt as claimed in ~~any~~ claim 10, wherein, when R³ is optionally substituted C₃₋₈cycloalkyl, then R³ is C₆₋₇cycloalkyl optionally substituted with one or two substituents independently ~~being selected from the group consisting of~~ OH; -C(O)NHR²⁴ wherein R²⁴ is H; oxo (~~=O~~) ~~or and~~ hydroxyimino (~~=N-OH~~).
12. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim,~~ wherein, for R³, the one or two optional R³ substituents if present ~~is or are~~ substituent(s) ~~are~~:
- (a) at the 3-position of a R³ cyclobutyl ring, or
 - (b) at the 3- and/or 4- position(s) of a R³ cyclopentyl or cyclopentenyl ring, or
 - (c) at the 3-, 4- and/or 5- position(s) of a R³ cyclohexyl or cyclohexenyl ring, or
 - (d) at the 3-, 4-, 5- and/or 6- position(s) of a R³ cycloheptyl or cycloheptenyl ring, or
 - (e) at the 3-, 4-, 5-, 6- and/or 7- position(s) of a R³ cyclooctyl ring,
- ~~and/or~~
- (f) at the 1-, 2- and/or highest-numbered- position(s) of a R³ cycloalkyl or cycloalkenyl ring, for alkyl or fluoroalkyl substituent(s), ~~and/or~~
 - (g) at the 2- ~~and/or~~ highest-numbered- position(s) of a R³ cycloalkyl or cycloalkenyl ring, for NHR²¹ substituent(s).
13. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim,~~ wherein, when R³ is the heterocyclic group of sub-formula (aa), (bb) or (cc), then Y is O or NR¹⁰.

14. (currently amended) A compound or salt as claimed in claim 1 any preceding claim, wherein R¹⁰ is H, C(O)NH₂ or C(O)methyl.
15. (original) A compound or salt as claimed in claim 14, wherein R¹⁰ is C(O)NH₂.
16. (currently amended) A compound or salt as claimed in claim 1 any preceding claim, wherein, when R³ is the heterocyclic group of sub-formula (aa), (bb) or (cc), then R³ is the heterocyclic group of sub-formula (bb) and n¹ is 1.
17. (canceled).
18. (currently amended) A compound or salt as claimed in claim 1 any preceding claim, wherein:
when R³ is optionally substituted mono-unsaturated-C₅₋₇cycloalkenyl, it is mono-unsaturated-cyclohexenyl optionally substituted with one or two substituents ~~independently being which are~~ fluoro or methyl;
and when R³ is a bicyclic group of sub-formula (ee), then Y¹, Y² and Y³ are all CH₂.
19. (currently amended) A compound or salt as claimed in claim 1 any preceding claim, wherein NHR³ is of sub-formula (a), (a1), (b), (c), (c 1), (c 2), (c 3), (c 4), (c 5), (c 6), (c 7), (d), (e), (f), (g), (g1), (g2), (g3), (g4), (h), (i), (j), (k), (k1), (k2), (L), (m), (m1), (m2), (m3), (m5), (n), (o), (o1), (o2), (o3), (p), (p1), (p2), (p3), (p4), (p5), (p6), (p7), (p8), (p9), (p10), (p11) or (q):



20. (currently amended) A compound or salt as claimed in claim 19, wherein NHR^3 is of sub-formula (c), (c1), (c 4), (c 5), (h), (i), (j), (k), (k2), (m1), (m2), (n), (o), (o2), (o3), (p2), (p5), (p6), (p9), (p11) or (q).
21. (currently amended) A compound or salt as claimed in claim 19, wherein NHR^3 is of sub-formula (c), (p11), (h), (k2), (n), (o), (o2) or (p9).
22. (currently amended) A compound or salt as claimed in claim 19, ~~20 or 21~~, wherein:
when NHR^3 is of sub-formula (n), then it is in the *cis* configuration, ~~i.e. it is a *cis*-(3-hydroxycyclohexan-1-yl)amino group~~; and
when NHR^3 is of sub-formula (p9), then it is in the *cis* configuration, ~~i.e. it is a *cis*-[4-(aminocarbonyl)cyclohexan-1-yl]amino group~~.
23. (currently amended) A compound or salt as claimed in claim 19, wherein NHR^3 is of sub-formula (h) or (k2), that is R^3 is tetrahydro-2H-pyran-4-yl or 1-(aminocarbonyl)-4-piperidinyl.
24. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim~~, wherein R^4 is ~~a hydrogen atom (H) hydrogen~~, methyl, ethyl, C_1 fluoroalkyl, $-\text{CH}_2\text{OH}$, $-\text{CH}(\text{Me})\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OH}$, or $-\text{CH}_2\text{OMe}$.
25. (currently amended) A compound or salt as claimed in claim 24, wherein R^4 is ~~a hydrogen atom (H) hydrogen~~, methyl, ethyl, $-\text{CH}_2\text{OH}$, or $-\text{CH}_2\text{OMe}$.
26. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim~~, wherein R^5 is ~~a hydrogen atom (H) hydrogen~~, methyl, ethyl, n-propyl, or iso-propyl.
27. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim~~, wherein, in sub-formula (x):
two or more of A, B, D, E and F are C-H (~~carbon hydrogen~~); and one or more others of A, B, D, E and F are independently C-H (~~carbon hydrogen~~), C-F (~~carbon fluorine~~), C-Cl (~~carbon chlorine~~), C-Me, C-OMe, or nitrogen (~~N~~);
no more than one of A, B, D, E and F is nitrogen; and
~~none of excluding compounds where~~ A, B, D, E and F are nitrogen-oxide (N^+-O^-).
28. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim~~, wherein Ar ~~has is~~ the sub-formula (x).
29. (currently amended) A compound or salt as claimed in claim 28, wherein Ar ~~has the sub-formula (x), and the sub-formula (x)~~ is sub-formula (x1), (x2), (x3), (x4), (x5), (x6), (x7), (x8), (x9), (x10), (x11), (x12), (x13), (x14), (x15) or (x16):



(x1)



(x2)



(x3)



(x4)



(x5)




(x6)




(x7)




(x8)




(x9)




(x10)




(x11)



(x12)



(x13)



(x14)



(x15)



(x16)

30. (currently amended) A compound or salt as claimed in claim 29, wherein Ar ~~has the sub-formula (x), and the sub-formula (x)~~ is sub-formula (x1).

31. (currently amended) A compound or salt as claimed in claim 30, wherein Ar ~~is of sub-formula (x1) and is:~~ monoalkyl-phenyl-, mono(fluoroalkyl)-phenyl-, monohalo-phenyl-, monoalkoxy-phenyl-, mono(fluoroalkoxy)-phenyl-, dialkyl-phenyl-, monoalkyl-monohalo-phenyl-, dihalo-phenyl- or dihalo-monoalkyl-phenyl-.

32. (original) A compound or salt as claimed in claim 31, wherein Ar is: monoC₁₋₄alkyl-phenyl-; monoC₁fluoroalkyl-phenyl-; monoC₁₋₃alkoxy-phenyl-; mono(C₁fluoroalkoxy)-phenyl-; diC₁₋₃alkyl-phenyl-; monoC₁₋₃alkyl-monohalo-phenyl-; dihalo-phenyl-; or dihalo-monoC₁₋₂alkyl-phenyl-.

33. (currently amended) A compound or salt as claimed in ~~claim 1 any preceding claim,~~ wherein, in sub-formula (x), R^{6A}, R^{6B}, R^{6D}, R^{6E} and R^{6F}, independently of each other, are: ~~a hydrogen atom (H) hydrogen,~~ a fluorine, chlorine or bromine atom, methyl, ethyl, n-propyl,


isopropyl, trifluoromethyl, -CH₂OH, methoxy, ethoxy, n-propoxy, difluoromethoxy, OH or MeS(O)₂-.

34. (currently amended) A compound or salt as claimed in claim 1 ~~any preceding claim~~, wherein

R⁹ is a ~~hydrogen atom (H)~~ hydrogen or methyl;

R^{6J}, R^{6L}, R^{6M} and R^{6Q} independently are H, OH ~~(including any keto-tautomer thereof)~~; C₁₋₂alkyl or C₁ fluoroalkyl; and

when Ar has the sub-formula (z), then sub-formula (z), then sub-formula (z) is one of the following:



35. (currently amended) A compound or salt as claimed in claim 1, which is ~~one of~~ Examples 1 to 29,

N-[(4-chloro-2-methylphenyl)methyl]-6-cyclopropyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

N-[(4-chloro-2-methylphenyl)methyl]-6-cyclopropyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

6-cyclopropyl-1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

6-cyclopropyl-1-ethyl-N-[[4-(methyloxy)phenyl]methyl]-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

6-cyclopropyl-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

N-[1-(4-chlorophenyl)ethyl]-6-cyclopropyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

N-[1-(4-chlorophenyl)propyl]-6-cyclopropyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

1-ethyl-N-(phenylmethyl)-6-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

1-ethyl-N-([4-(methoxy)phenyl]methyl)-6-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl-6-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-[(3,4-dimethylphenyl)methyl]-1-ethyl-6-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-6-propyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
1,6-diethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
1,6-diethyl-N-([4-(methoxy)phenyl]methyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-[(3,4-dimethylphenyl)methyl]-1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-(2,3-dihydro-1H-inden-2-yl)-1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-[1-(4-chlorophenyl)propyl]-1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
6-cyclobutyl-1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
6-cyclobutyl-1-ethyl-N-([4-(methoxy)phenyl]methyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
6-(cyclopropylmethyl)-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
6-cyclobutyl-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-[(4-chloro-2-methylphenyl)methyl]-6-cyclobutyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-[1-(4-chlorophenyl)ethyl]-6-cyclobutyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-[1-(4-chlorophenyl)propyl]-6-cyclobutyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
6-(cyclopropylmethyl)-1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
6-(cyclopropylmethyl)-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;

6-(cyclopropylmethyl)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-[1-(4-chlorophenyl)ethyl]-6-(cyclopropylmethyl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
6-cyclopentyl-1-ethyl-N-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide; and
6-cyclopentyl-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide,
as a compound or a pharmaceutically acceptable salt thereof.

36. (canceled).

37. (currently amended) A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in ~~any of claims 1 to 35,~~ claim 1 and one or more pharmaceutically acceptable carriers and/or excipients.

Claims 38–39 (canceled).

40. (currently amended) A method of treatment and/or prophylaxis of an inflammatory and/or allergic disease in a human in need thereof, which method comprises administering to the human a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in ~~any of claims 1 to 35~~ claim 1.